Docum<strong>en</strong>to <strong>de</strong>scargado <strong>de</strong> http://www.<strong>el</strong>sevier.es <strong>el</strong> 27/01/2013. Copia <strong>para</strong> uso personal, se prohíbe <strong>la</strong> transmisión <strong>de</strong> este docum<strong>en</strong>to por cualquier medio o formato.<strong>Recom<strong>en</strong>daciones</strong> <strong>para</strong> <strong>la</strong> <strong>de</strong>terminación <strong>de</strong> <strong>biomarcadores</strong> <strong>en</strong> <strong>el</strong> carcinoma <strong>de</strong> pulmón no microcítico avanzado 27never-smokers with advanced or metastatic a<strong>de</strong>nocarcinoma ofthe lung [abstract]. J Thorac Oncol. 2009;4 Suppl 1:PRS4.8. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I,Tsurutani J, et al. Gefitinib versus cisp<strong>la</strong>tin plus docetax<strong>el</strong> inpati<strong>en</strong>ts with non-small-c<strong>el</strong>l lung cancer harbouring mutationsof the epi<strong>de</strong>rmal growth factor receptor (WJTOG3405): An op<strong>en</strong><strong>la</strong>b<strong>el</strong>, randomised phase 3 trial. Lancet Oncol. 2010;11:121 -8.9. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S,Isobe H, et al. Gefitinib or chemotherapy for non-small-c<strong>el</strong>l lungcancer with mutated EGFR. N Engl J Med. 2010;362:2380 -8.10. Zhou C, Wu YL, Ch<strong>en</strong> G, F<strong>en</strong>g J, Liu X, Wang C. Efficacy resultsfrom the randomized phase III OPTIMAL (CTONG 0802) studycomparing first-line erlotinib versus carbop<strong>la</strong>tin (CBDCA) plusgemcitabine (GEM), in Chinese advanced non-small-c<strong>el</strong>l lungcancer (NSCLC) pati<strong>en</strong>ts (PTS) with EGFR activating mutations[abstract]. Ann Oncol. 2010;21:LBA13.11. Ros<strong>el</strong>l R, Gervais R, Vergn<strong>en</strong>egre A, Massuti B, F<strong>el</strong>ip E,Car<strong>de</strong>nal F, et al. Erlotinib versus chemotherapy (CT) in advancednon-small c<strong>el</strong>l lung cancer (NSCLC) pati<strong>en</strong>ts (p) withepi<strong>de</strong>rmal growth factor receptor (EGFR) mutations: Interimresults of the European Erlotinib Versus Chemotherapy (EURTAC)phase III randomized trial [abstract]. En: ASCO Annual Meeting.2011. p. 7503.12. F<strong>el</strong>ip E, Gri<strong>de</strong>lli C, Baas P, Ros<strong>el</strong>l R, Stah<strong>el</strong> R. Metastatic nonsmall-c<strong>el</strong>llung cancer: Cons<strong>en</strong>sus on pathology and molecu<strong>la</strong>rtests, first-line, second-line, and third-line therapy: 1st ESMOCons<strong>en</strong>sus Confer<strong>en</strong>ce in Lung Cancer; Lugano 2010. Ann Oncol.2011;22:1507 -19.13. Keedy VL, Temin S, Somerfi<strong>el</strong>d MR, Beasley MB, Johnson DH,McShane LM, et al. American Society of Clinical Oncology provisionalclinical opinion: Epi<strong>de</strong>rmal growth factor receptor (EGFR)Mutation testing for pati<strong>en</strong>ts with advanced non-small-c<strong>el</strong>l lungcancer consi<strong>de</strong>ring first-line EGFR tyrosine kinase inhibitor therapy.J Clin Oncol. 2011;29:2121 -7.14. Trigo Perez JM, Garrido Lopez P, F<strong>el</strong>ip Font E, Is<strong>la</strong> Casado D.SEOM clinical gui<strong>de</strong>lines for the treatm<strong>en</strong>t of non-small-c<strong>el</strong>l lungcancer: An updated edition. Clin Transl Oncol. 2010;12:735 -41.15. Morris SW, Kirstein MN, Val<strong>en</strong>tine MB, Dittmer KG, Shapiro DN,Saltman DL, et al. Fusion of a kinase g<strong>en</strong>e, ALK, to a nucleo<strong>la</strong>rprotein g<strong>en</strong>e, NPM, in non-Hodgkin’s lymphoma. Sci<strong>en</strong>ce.1994;263:1281 -4.16. Chiarle R, Vo<strong>en</strong>a C, Ambrogio C, Piva R, Inghirami G. The anap<strong>la</strong>sticlymphoma kinase in the pathog<strong>en</strong>esis of cancer. Nat RevCancer. 2008;8:11 -23.17. Rikova K, Guo A, Z<strong>en</strong>g Q, Possemato A, Yu J, Haack H, et al.Global survey of phosphotyrosine signaling i<strong>de</strong>ntifies oncog<strong>en</strong>ickinases in lung cancer. C<strong>el</strong>l. 2007;131:1190 -203.18. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S,et al. I<strong>de</strong>ntification of the transforming EML4-ALK fusion g<strong>en</strong>ein non-small-c<strong>el</strong>l lung cancer. Nature. 2007;448:561 -6.19. Weinstein IB, Joe A. Oncog<strong>en</strong>e addiction. Cancer Res.2008;68:3077 -80, discussion 3080.20. Sasaki T, Rodig SJ, Chirieac LR, Janne PA. The biology and treatm<strong>en</strong>tof EML4-ALK non-small c<strong>el</strong>l lung cancer. Eur J Cancer.2010;46:1773 -80.21. Shaw AT, Yeap BY, Mino-K<strong>en</strong>udson M, Digumarthy SR, Costa DB,Heist RS, et al. Clinical features and outcome of pati<strong>en</strong>ts withnon-small-c<strong>el</strong>l lung cancer who harbor EML4-ALK. J Clin Oncol.2009;27:4247 -53.22. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG,et al. Anap<strong>la</strong>stic lymphoma kinase inhibition in non-small-c<strong>el</strong>llung cancer. N Engl J Med. 2010;363:1693 -703.23. Ding L, Getz G, Whe<strong>el</strong>er DA, Mardis ER, McL<strong>el</strong><strong>la</strong>n MD,Cibulskis K, et al. Somatic mutations affect key pathways inlung a<strong>de</strong>nocarcinoma. Nature. 2008;455:1069 -75.24. Beau-Faller M, Ruppert AM, Voeg<strong>el</strong>i AC, Neuville A, Meyer N,Guerin E, et al. MET g<strong>en</strong>e copy number in non-small c<strong>el</strong>l lungcancer: Molecu<strong>la</strong>r analysis in a targeted tyrosine kinase inhibitornaive cohort. J Thorac Oncol. 2008;3:331 -9.25. E<strong>de</strong>r JP, Van<strong>de</strong> Wou<strong>de</strong> GF, Boerner SA, LoRusso PM. Nov<strong>el</strong> therapeuticinhibitors of the c-Met signalling pathway in cancer. ClinCancer Res. 2009;15:2207 -14.26. Hirsch FR, Langer CJ. The role of HER2/neu expression andtrastuzumab in non-small c<strong>el</strong>l lung cancer. Semin Oncol.2004;31:75 -82.27. Perera SA, Li D, Shimamura T, Raso MG, Ji H, Ch<strong>en</strong> L, et al.HER2YVMA drives rapid <strong>de</strong>v<strong>el</strong>opm<strong>en</strong>t of a<strong>de</strong>nosquamous lungtumors in mice that are s<strong>en</strong>sitive to BIBW2992 and rapamycincombination therapy. Proc Natl Acad Sci U S A. 2009;106:474 -9.28. Shimamura T, Ji H, Minami Y, Thomas RK, Low<strong>el</strong>l AM, Shah K,et al. Non-small-c<strong>el</strong>l lung cancer and Ba/F3 transformed c<strong>el</strong>lsharboring the ERBB2 G776insV G/C mutation are s<strong>en</strong>sitive tothe dual-specific epi<strong>de</strong>rmal growth factor receptor and ERBB2inhibitor HKI-272. Cancer Res. 2006;66:6487 -91.29. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S,et al. HER2 kinase domain mutation results in constitutivephosphory<strong>la</strong>tion and activation of HER2 and EGFR and resistanceto EGFR tyrosine kinase inhibitors. Cancer C<strong>el</strong>l. 2006;10:25 -38.30. Paik PK, Arci<strong>la</strong> ME, Fara M, Sima CS, Miller VA, Kris MG, et al.Clinical characteristics of pati<strong>en</strong>ts with lung a<strong>de</strong>nocarcinomasharboring BRAF mutations. J Clin Oncol. 2011;29:2046 -51.31. Oku<strong>de</strong><strong>la</strong> K, Suzuki M, Kageyama S, Bunai T, Nagura K, Igarashi H,et al. PIK3CA mutation and amplification in human lung cancer.Pathol Int. 2007;57:664 -71.32. Kawano O, Sasaki H, Endo K, Suzuki E, Haneda H, Yukiue H,et al. PIK3CA mutation status in Japanese lung cancer pati<strong>en</strong>ts.Lung Cancer. 2006;54:209 -15.33. Angulo B, Suarez-Gauthier A, Lopez-Rios F, Medina PP, Con<strong>de</strong> E,Tang M, et al. Expression signatures in lung cancer revea<strong>la</strong> profile for EGFR-mutant tumours and i<strong>de</strong>ntify s<strong>el</strong>ectivePIK3CA overexpression by g<strong>en</strong>e amplification. J Pathol.2008;214:347 -56.34. Travis WD, Brambil<strong>la</strong> E, Müller-Herm<strong>el</strong>ink HK, Harris CC. WHOC<strong>la</strong>ssification. Pathology & G<strong>en</strong>etics ---- Tumors of the Lung,Pleura, Thymus and Heart. 2004 [consultado 1 Juni 2011]; disponible<strong>en</strong>: http://www.iarc.fr/<strong>en</strong>/publications/pdfs-online/patg<strong>en</strong>/bb10/bb10-cover.pdf35. Salido M, Pijuan L, Martinez-Aviles L, Galvan AB, Canadas I,Rovira A, et al. Increased ALK g<strong>en</strong>e copy number and amplificationare frequ<strong>en</strong>t in non-small c<strong>el</strong>l lung cancer. J ThoracOncol. 2011;6:21 -7.36. Sharma SV, Haber DA, Settleman J. C<strong>el</strong>l line-based p<strong>la</strong>tformsto evaluate the therapeutic efficacy of candidate anticancerag<strong>en</strong>ts. Nat Rev Cancer. 2010;10:241 -53.37. SEAP-IAP. Garantía <strong>de</strong> Calidad <strong>en</strong> Patología <strong>de</strong> <strong>la</strong> SociedadEspaño<strong>la</strong> <strong>de</strong> Anatomía Patológica y <strong>la</strong> División Españo<strong>la</strong> <strong>de</strong>l InternationalAca<strong>de</strong>my of Pathology. 2011 [consultado 1 Juni 2011];disponible <strong>en</strong>: http://www.seap.es/gcp/molecu<strong>la</strong>r/in<strong>de</strong>x.asp38. Travis WD, Brambil<strong>la</strong> E, Noguchi M, Nicholson AG, Geisinger KR,Yatabe Y, et al. International Association for the Study ofLung Cancer/American Thoracic Society/European RespiratorySociety international multidisciplinary c<strong>la</strong>ssification of lunga<strong>de</strong>nocarcinoma. J Thorac Oncol. 2011;6:244 -85.39. Mukhopadhyay S, Katz<strong>en</strong>stein AL. Subc<strong>la</strong>ssification of non-smallc<strong>el</strong>l lung carcinomas <strong>la</strong>cking morphologic differ<strong>en</strong>tiation onbiopsy specim<strong>en</strong>s: Utility of an immunohistochemical pan<strong>el</strong> containingTTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol.2011;35:15 -25.40. Boldrini L, Gisfredi S, Ursino S, Camacci T, Baldini E, M<strong>el</strong>fi F,et al. Mutational analysis in cytological specim<strong>en</strong>s of advancedlung a<strong>de</strong>nocarcinoma: A s<strong>en</strong>sitive method for molecu<strong>la</strong>rdiagnosis. J Thorac Oncol. 2007;2:1086 -90.
Docum<strong>en</strong>to <strong>de</strong>scargado <strong>de</strong> http://www.<strong>el</strong>sevier.es <strong>el</strong> 27/01/2013. Copia <strong>para</strong> uso personal, se prohíbe <strong>la</strong> transmisión <strong>de</strong> este docum<strong>en</strong>to por cualquier medio o formato.28 J.J. Gómez et al41. Ladanyi M, Pao W. Lung a<strong>de</strong>nocarcinoma: Guiding EGFRtargetedtherapy and beyond. Mod Pathol. 2008;21 Suppl2:S16 -22.42. Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D,et al. Cons<strong>en</strong>sus for EGFR mutation testing in non-small c<strong>el</strong>llung cancer: Results from a European workshop. J Thorac Oncol.2010;5:1706 -13.43. Angulo B, Garcia-Garcia E, Martinez R, Suarez-Gauthier A,Con<strong>de</strong> E, Hidalgo M, et al. A commercial real-time PCR kit provi<strong>de</strong>sgreater s<strong>en</strong>sitivity than direct sequ<strong>en</strong>cing to <strong>de</strong>tect KRASmutations: A morphology-based approach in colorectal carcinoma.J Mol Diagn. 2010;12:292 -9.44. Brevet M, Arci<strong>la</strong> M, Ladanyi M. Assessm<strong>en</strong>t of EGFR mutationstatus in lung a<strong>de</strong>nocarcinoma by immunohistochemistry usingantibodies specific to the two major forms of mutant EGFR. JMol Diagn. 2010;12:169 -76.45. Con<strong>de</strong> E, Angulo B, Tang M, Mor<strong>en</strong>te M, Torres-Lanzas J, Lopez-Encu<strong>en</strong>tra A, et al. Molecu<strong>la</strong>r context of the EGFR mutations:Evi<strong>de</strong>nce for the activation of mTOR/S6 K signaling. Clin CancerRes. 2006;12:710 -7.46. Kato Y, P<strong>el</strong>ed N, Wynes MW, Yoshida K, Pardo M, Mascaux C,et al. Nov<strong>el</strong> epi<strong>de</strong>rmal growth factor receptor mutation-specificantibodies for non-small c<strong>el</strong>l lung cancer: Immunohistochemistryas a possible scre<strong>en</strong>ing method for epi<strong>de</strong>rmal growth factorreceptor mutations. J Thorac Oncol. 2010;5:1551 -8.47. Kawahara A, Yamamoto C, Nakashima K, Azuma K, Hattori S,Kashihara M, et al. Molecu<strong>la</strong>r diagnosis of activating EGFRmutations in non-small c<strong>el</strong>l lung cancer using mutation-specificantibodies for immunohistochemical analysis. Clin Cancer Res.2010;16:3163 -70.48. Marchetti A, Normanno N, Pinto C, Tad<strong>de</strong>i GL, Adamo V,Ardizzoni A, et al. Recomm<strong>en</strong>dations for mutational analysis ofEGFR in lung carcinoma. Pathologica. 2010;102:119 -26.49. Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reactionbased<strong>de</strong>tection of epi<strong>de</strong>rmal growth factor receptorg<strong>en</strong>e mutations in lung a<strong>de</strong>nocarcinomas. J Mol Diagn.2005;7:396 -403.50. Pao W, Ladanyi M. Epi<strong>de</strong>rmal growth factor receptor mutationtesting in lung cancer: Searching for the i<strong>de</strong>al method. ClinCancer Res. 2007;13:4954 -5.51. Yu J, Kane S, Wu J, B<strong>en</strong>e<strong>de</strong>ttini E, Li D, Reeves C, et al. Mutationspecificantibodies for the <strong>de</strong>tection of EGFR mutations in nonsmall-c<strong>el</strong>llung cancer. Clin Cancer Res. 2009;15:3023 -8.52. Travis WD, Rekhtman N. Pathological diagnosis and c<strong>la</strong>ssificationof lung cancer in small biopsies and cytology: Strategic managem<strong>en</strong>tof tissue for molecu<strong>la</strong>r testing. Semin Respir Crit CareMed. 2011;32:22 -31.53. Bil<strong>la</strong>h S, Stewart J, Staerk<strong>el</strong> G, Ch<strong>en</strong> S, Gong Y, Guo M. EGFR andKRAS mutations in lung carcinoma: Molecu<strong>la</strong>r testing by usingcytology specim<strong>en</strong>s. Cancer Cytopathol. 2011;119:111 -7.
Change language